Catalent Biologics Content
-
Achieving A Successful Drug Product Technology Transfer
Get insights on key considerations for a successful process transfer for manufacturing a drug product, including a case study on overcoming challenges in a process transfer for a sterile diluent.
-
Reaching First-In-Human Trials Faster: Connect With The Right Partner
Assessing outsourcing partners’ credentials in people, technology, supply chains, and integration will make all the difference as sponsors aim to streamline processes on the path to commercialization.
-
SMARTag Technology, From Bertozzi Lab To Best-In-Class ADCs
Hear experts discuss the latest trends in antibody-drug conjugate (ADC) discovery and development and how next-generation pipelines are being shaped by payload and linker-chemistry innovations.
-
Generating A Fully Processed Antibody
Discover cell-line development and process scale-up for an antibody program where the antibody requires additional processing by a site-specific enzyme for correct functionality.
-
Elemental Impurities Risk Assessment For Finished Drug Products
Review the impact of regulatory changes related to elemental impurities testing, guidance on the best routes to compliance, and an overview of the elemental impurities risk assessment process.
-
Getting Your Biologic To Clinic Faster & More Efficiently
There are a range of benefits to use an integrated supplier to streamline biologic drug development starting in early phase through clinical and commercial stages.
-
European Center Of Excellence For Clinical Biologics
Explore how our proven expertise and simplified execution with development, filling, and analytical under one roof ensure safe, efficacious products reach patients in need.
-
Keys To A Successful Rapid Commercial Launch
Combining a rapid launch following regulatory approval with effective messaging and post-launch services can provide a competitive advantage.
-
Leveraging Bio-Functional Assays For Charged Variants Characterization
The heterogeneity of a biologic product has implications for the final therapy's safety and efficacy. Explore challenges associated with charged variants, including mAbs and fusion proteins.